Biologic approaches to treatment-refractory obsessive-compulsive disorder

Psychiatric Annals

Volumn 28, Issue 11, 1998, Pages 641-649

  Goodman, Wayne K ^b   Ward, Herbert E ^b   Murphy, Tanya K ^a,b  

^a Department of Child Psychiatry ^*

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11544304099     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19981101-09     Document Type: Article

References (87)

1. Griest JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a metaanalysis. Arch Gen Psychiatry. 1995;52:53-60.
2. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
3. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part II. Validity. Arch Gen Psychiatry. 1989;46:1012-1016.
4. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Presented at: ACNP meeting, 1993; Hawaii. Abstract.
5. Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
6. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
7. Baer L, Jenike MA, Black DW, et al. Effect of Axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive compulsive disorder. Arch Gen Psychiatry. 1992;49:862-866.
8. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive compulsive disorder. J Clin Psychiatry. 1995;56:368-373.
9. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993;13:354-358.
10. Rachman SI, Hodgson RJ. Primary obsessional slowness. In: Jenkins JJ, Mischel W, Hartap WH, eds. Obsessions and Compulsions. Englewood Cliffs, NJ: Prentice-Hall; 1980:223-234.
11. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990;51(Suppl):36-43.
12. Byerly MJ, Goodman WK, Christensen R. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1996;153:1232-1233. Letter.
13. Zohar J, Rajinder J. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry. 1996;169:468-474.
14. Koran LM, McElroy SL, Davidson JRT, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol. 1996;16:121-129.
15. Jenike MA, Surman OS, Cassem NH, et al. Monoamine oxidase inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1983;144:131-132.
16. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997;154:1261-1264.
17. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419-423.
18. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990;10:152-153. Letter.
19. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry. 1996;153:576-577. Letter.
20. Ananth J, Burgoyne K, Smith M, Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1832-1833.
21. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol. 1996;16:81-84.
22. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:653-654. Letter.
23. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry. 1994;55:234-241.
24. Sofuoglu M, Debattista C. Development of obsessive symptoms during nefazodone treatment. Am J Psychiatry. 1996;153:577-578. Letter.
25. van Balkom AJLM, van Oppen P, Vermeulen AWA, van Dyck R, Nauta MCE, Vorst HCM. A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clin Psychol Rev. 1994;14:5:359-381.
26. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine resistant obsessive-compulsive disorder. Am J Psychiatry. 1984;141:1283-1285.
27. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry. 1986;21:1067-1071.
28. Hertzman PA, Blevins WL, Mayer J, et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990;322:869-873.
29. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996;11:37-44.
30. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry. 1990;51:119-123.
31. Judd FK, Chua P, Lynch C, et al. Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder. Aus N Z J Psychiatry. 1991;25:412-414.
32. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
33. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry. 1983;40:1335-1342.
34. Blier P, de Montigny C. Lack of efficacy of lithium augmentation in obsessive-compulsive disorder: the perspective of different regional effects of lithium on serotonin release in the central nervous system. J Clin Psychopharmacol. 1992;12:65-66.
35. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991; 11:242-248.
36. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991;11:175-184.
37. Grady TA, Pigott TA, L'Heureux FL, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150:819-821.
38. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993;150:647-649.
39. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12:11-18.
40. Wagner HR, Reches A, Yablonskaya E, et al. Clonazepam-induced up-regulation of serotonin-1 and serotonin-2 binding sites in rat frontal cortex. Adv Neurol. 1986;43:645-651.
41. Jenike MA. Drug treatment of obsessive-compulsive disorder. In: Jenike MJ, Baer L, Minichiello WE, eds. Obsessive Compulsive Disorders: Practical Management, 3rd ed. St. Louis: Mosby; 1998;469-532.
42. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069-1072.
43. 1A antagonists. Trends-Neurosci. 1996;19:378-383.
44. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217-222.
45. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154:37-43.
46. Koran LM, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? J Clin Psychopharmacol. 1996;16:253-254. Letter.
47. Byerly MJ, Goodman WK. Adjunctive pindolol in fluoxetine treated patients with obsessive compulsive disorder. Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997; Waikoloa, Hawaii.
48. 1A autoreceptor in vivo. Br J Pharmacol. 1998;124:206-212.
49. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull. 1990; 26:285-290.
50. Browne M, Horn E, Jones TT. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry. 1993;38:242-243.
51. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Cin Psychiatry. 1996;57:257-264.
52. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive compulsive disorder. Am J Psychiatry. 1997;154:1293-1295.
53. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.
54. Leckman JF, Pauls DL, Cohen DJ. Tic disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995:1665-1674.
55. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette's syndrome. Lancet. 1994;344:1577-1578.
56. van der Linden C, Bruggeman R, van Woerkom T. Serotonin-dopamine antagonist and Gilles de La Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994;9:687-688.
57. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adoles Psych. 1995;34:1147-1152.
58. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996;57:29-31.
59. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995;56:526-528.
60. Jacobsen FM. Risperidone in the treatment of severe affective illness and refractory OCD. J Clin Psychiatry. 1995;56:423-429.
61. Saxena S, Wang D, Bystritsky A, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996;57:303-306.
62. Giakas WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1097-1098. Letter.
63. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive compulsive disorder. Am J Psychiatry. 1994;152: 1812-1814.
64. Fallon BA, Campeas R, Schneier FR, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1992;4:70-75.
65. Warneke LB. Intravenous chlorimipramine therapy in obsessive-compulsive disorder. Can J Psychiatry. 1989; 34:853-859.
66. Thakur AK, Remillard AJ, Meldrum LH, et al. Intravenous clomipramine and obsessive-compulsive disorder. Can J Psychiatry. 1991;36:521-524.
67. Fallon BA, Campeas R, Schneier F, Davies S, Liebowitz MR. IV clomipramine for refractory OCD: a controlled study. New Research 448. American Psychiatric Association; Philadelphia; 1994. Abstract.
68. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:396-401.
69. Leckman JF, Goodman WK, North WG, et al. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology. 1994;19:723-749.
70. Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology. 1987;12:231-236.
71. Den Boer JA, Westenberg GM. Oxytocin in obsessive compulsive disorder. Peptides. 1992;13:1083-1085.
72. Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand. 1986;73:221-222.
73. Feldman JD, Noshirvani H, Chu C. Improvement in female patients with severe obsessions and/or compulsions treated with cyproterone acetate. Acta Psychiatr Scand. 1988;78:254. Letter.
74. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996;153:1219-1221.
75. Chouinard G, Belanger M-C, Beauclair L, Sultan S, Murphy BEP. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive compulsive disorder resistant to SSRIs: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 1996; 20:1067-1079.
76. Swedo SE, Leonard HL, Kiessling LS. Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics. 1994;93:323-326.
77. Swedo SE, Rapoport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989;146:2: 246-249.
78. Murphy TK, Goodman WK, Fudge MW, et al. B lymphocyte antigen D8/17: a peripheral marker for Tourette's syndrome and childhood-onset obsessive compulsive disorder? Am J Psychiatry. 1997;154:402-407.
79. Rudorfer MV. ECT in treatment refractory obsessive compulsive disorder. In: Goodman WK, Rudorfer MD, Maser JD, eds. Obsessive Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: Lawrence Erlbaum & Associates Publishers. In press.
80. Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder. Am J Psychiatry. 1993;150:1899-1900. Letter.
81. Khanna S, Gangadhar BN, Sinha V, et al. Electroconvulsive therapy in obsessive-compulsive disorder. Convul Ther. 1988;4:314-320.
82. Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J Neuropsychiatry. 1994;6:467-477.
83. Jenike MA, Baer L, Ballantine HT, et al. Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 patients. Arch Gen Psychiatry. 1991;48:548-555.
84. Baer L, Rauch SL, Ballantine T, et al. Cingulotomy for intractable obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:384-392.
85. George MS, Wasserman EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport. 1995;6:1853-1856.
86. Greenberg BD, George MS, Martin DJ, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive compulsive disorder: a preliminary study. Am J Psychiatry. 1997;154:687-869.
87. Wasserman EM. Repetitive transcranial magnetic stimulation: an introduction and overview. CNS Spectrums. 1997;2:21-25.